Seminars in ophthalmology · 2025
Uses of Autologous Serum in Ocular Surface Diseases: A 10-Year Experience and Review of the Literature.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Domínguez-López Alfredo, Buentello-Volante Beatriz, Magaña-Guerrero Norma, Magaña-Guerrero Fátima Sofía, Vivanco-Rojas Óscar, Graue Hernández Enrique O, Garfias Yonathan
Аннотация
PURPOSE: The aim of this study was to identify the diagnoses that led to the prescription of autologous serum (AS) in a tertiary eye care center over a 10-year period and to contextualize these findings through a comprehensive review of the literature.
METHODS: A retrospective case series was conducted including records of patients who were prescribed AS for the first time between January 2015 and December 2024. In parallel, we analyzed more than 30 clinical studies, including randomized controlled trials and observational reports, investigating the efficacy, safety, and concentration strategies of AS in various ocular surface diseases.
RESULTS: A total of 1,108 patients were included (mean age: 60.6±15.9 years; 81% female), with most patients between 50 and 79 years old. The most frequent diagnoses included non-Sjögren dry eye (36.4%), and primary (16.3%) and secondary (6.6%) Sjögrenös syndrome-related dry eye, with 20% and 30% being the most commonly prescribed concentrations. The literature supports the use of AS, particularly at a concentration of 20%, in conditions such as dry eye and Sjögren's syndrome, which is consistent with our findings.
CONCLUSIONS: This integrated analysis provides valuable insight into current clinical practice and may support future decision-making in the treatment of ocular surface disease.
METHODS: A retrospective case series was conducted including records of patients who were prescribed AS for the first time between January 2015 and December 2024. In parallel, we analyzed more than 30 clinical studies, including randomized controlled trials and observational reports, investigating the efficacy, safety, and concentration strategies of AS in various ocular surface diseases.
RESULTS: A total of 1,108 patients were included (mean age: 60.6±15.9 years; 81% female), with most patients between 50 and 79 years old. The most frequent diagnoses included non-Sjögren dry eye (36.4%), and primary (16.3%) and secondary (6.6%) Sjögrenös syndrome-related dry eye, with 20% and 30% being the most commonly prescribed concentrations. The literature supports the use of AS, particularly at a concentration of 20%, in conditions such as dry eye and Sjögren's syndrome, which is consistent with our findings.
CONCLUSIONS: This integrated analysis provides valuable insight into current clinical practice and may support future decision-making in the treatment of ocular surface disease.